Allele-specific mutation-agnostic gene therapy
Allele-specific mutation-agnostic gene therapy has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Mar 27, 2026: “Leveraging human genetic variation to therapeutically target hundreds of genes with dominant & dispensable disease alleles”.
InterventionPreclinical
1 paper studies it1 findingUpdated
See all 1 papers on allele-specific mutation-agnostic gene therapy
- In silico1
What did studies of allele-specific mutation-agnostic gene therapy find?
1Studies of allele-specific mutation-agnostic gene therapy measured one outcome, treatable patients.
Treatable patients
upin silico1
1 study
Treatable patients
upin silico1
Allele-specific mutation-agnostic gene therapy increases treatable patients in silico (>80 times).
“In some disease genes, this approach would allow >80 times as many patients to be treated as mutation-specific strategies.”
In silico
medRxivPreprint
Latest
1 paper in 12 monthsmedRxiv
Leveraging human genetic variation to therapeutically target hundreds of genes with dominant & dispensable disease alleles
Preprint: computational studyInterventions